Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019



Uta Griesenbach

Uta Griesenbach

Professor, Molecular Medicine, National Heart and Lung Institute, Imperial College London

Uta Griesenbach is a Professor in Molecular Medicine at the National Heart and Lung Institute, Imperial College London and the President of the British Society for Gene and Cell Therapy ( Uta‘s reserach interests are related to the development of gene therapy-based treatments for cystic fibrosis and other inflammatory lung diseases and include vector and biomarker development, toxicology and safety as well as GMP-vector production. Uta is Co-Investigator on several gene therapy trials, including a recently completed non-viral Phase IIb study. Uta is a Strategy Group Member of the UK Cystic Fibrosis Gene Therapy Consortium ( and is the Gene Therapy advisor (GTAC) on the West London National Research Ethics Comittee. In addition, Uta is interested in teaching and work-force development. She is Deputy-director for post-graduate reserach at the National Heart and Lung Institute and Programme director for the MSc in Genes, Drugs and Stem cells-Novel Therapies at Imperial College.  

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd